This supports early-phase translational research that will generate new vaccine candidates suitable for further downstream development and clinical evaluation. Studies that lead to discovery of new vaccine candidates that prevent infection, ameliorate disease or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax, are encouraged.
This opportunity uses the R01 Research Project Grant funding mechanism.
Funding & Duration
Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Date
- Applications submitted for internal review by 22 January 2019
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review